Cited by 892Cancer Cells and MetastasisAcute Lymphoblastic Leukemia researchDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Environment-mediated drug resistance: a major contributor to minimal residual disease

Meads, Mark B., Gatenby, Robert A., Dalton, William S.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Environment-mediated drug resistance is a form of de novo drug resistance that protects tumour cells from the initial effects of diverse therapies. Surviving foci of residual disease can then develop complex and permanent acquired resistance in response to the selective pressure of therapy. Recent evidence indicates that environment-mediated drug resistance arises from an adaptive, reciprocal signalling dialogue between tumour cells and the surrounding microenvironment. We propose that new therapeutic strategies targeting this interaction should be applied during initial treatment to prevent the emergence of acquired resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc2714

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Treatment of Acute Lymphoblastic Leukemia
Pui, C., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 2,012
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,847
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Ömeroğlu, G., Meterissian, S. H., Ömeroğlu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,707
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citation
Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,380
DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333

Flagged first, then by citations

Show all 109 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 201–300 of 892

A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas
Lwin, T., Zhao, X., Cheng, F., Zhang, X., Huang, A., Shah, B. D., Zhang, Y., Moscinski, L. C., Choi, Y. S., Kozikowski, A. P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64210 · Cited by 75
Self-citation
3D hydrogel-based microwell arrays as a tumor microenvironment model to study breast cancer growth
Casey, J., Yue, X., Nguyen, T. D., Acun, A., Zellmer, V. R., Zhang, S., & Zorlutuna, P. (2017) · Biomedical Materials · doi:10.1088/1748-605x/aa5d5c · Cited by 74
Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression
Tan, X., He, Y., Yang, J., Wei, X., Fan, Y., Zhang, G., Zhu, Y., Li, Z., Liao, H., Qin, D., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01248-9 · Cited by 80
Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion
Yu, K.-X., Yuan, W.-J., Wang, H.-Z., & Li, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03675-9 · Cited by 88
Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance
Sun, Y., & Nelson, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0768 · Cited by 74
Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis
Schlesinger, M., & Bendas, G. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9545-x · Cited by 73
c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
Delitto, D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8458 · Cited by 72
The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor
Won, J., Yang, H. W., Shin, S., Lee, J., Heo, W. D., & Cho, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs021 · Cited by 75
Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability
Shlush, L. I., Chapal-Ilani, N., Adar, R., Pery, N., Maruvka, Y. E., Spiro, A., Shouval, R., Rowe, J. M., Tzukerman, M., Bercovich, D., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388629 · Cited by 72
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications
Jakubı́ková, J., Cholujová, D., Hideshima, T., Gronesova, P., Šoltýsová, A., Harada, T., Joo, J., Kong, S., Szalat, R. E., Richardson, P. G. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12643 · Cited by 78
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Antonarakis, E. S., & Armstrong, A. J. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.23 · Cited by 74
Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies
Zhang, Y., Jiang, X., Zhang, N., Chen, M., Wang, H., & Zhu, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.017 · Cited by 69
Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression
Jena, B. C., Das, C. K., Bharadwaj, D., & Mandal, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188416 · Cited by 72
Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy
Cotechini, T., Atallah, A., & Grossman, A. (2021) · Cells · doi:10.3390/cells10040960 · Cited by 74
Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system
Raaijmakers, M. H. G. P. (2011) · Haematologica · doi:10.3324/haematol.2010.028035 · Cited by 71
Cancer Stem-like Cells Derived from Chemoresistant Tumors Have a Unique Capacity to Prime Tumorigenic Myeloid Cells
Yamashina, T., Baghdadi, M., Yoneda, A., Kinoshita, I., Suzu, S., Dosaka‐Akita, H., & Jinushi, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2169 · Cited by 70
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells
Javidi‐Sharifi, N., Martinez, J., English, I. A., Joshi, S. K., Scopim‐Ribeiro, R., Viola, S. K., Edwards, D. K., V, Agarwal, A., López, C. S., Jorgens, D. M., et al. (2019) · eLife · doi:10.7554/elife.40033 · Cited by 69
The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Sebens, S., & Schäfer, H. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112802501999 · Cited by 70
Disturbed CXCR 4/ CXCL 12 axis in paediatric precursor B‐cell acute lymphoblastic leukaemia
van den Berk, L. C. J., van der Veer, A., Willemse, M. E., Theeuwes, M., Luijendijk, M. W. J., Tong, W. H., van der Sluis, I. M., Pieters, R., & den Boer, M. L. (2014) · British Journal of Haematology · doi:10.1111/bjh.12883 · Cited by 69
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
Pittari, G., Vago, L., Festuccia, M. B., Bonini, C., Mudawi, D., Giaccone, L., & Bruno, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01444 · Cited by 73
Fibroblast-associated tumour microenvironment induces vascular structure-networked tumouroid
Lee, S. W., Kwak, H. S., Kang, M.-H., Park, Y.-Y., & Jeong, G. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-20886-0 · Cited by 68
Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Holthof, L. C., & Mutis, T. (2020) · Cancers · doi:10.3390/cancers12040988 · Cited by 68
Three-dimensional decellularized tumor extracellular matrices with different stiffness as bioengineered tumor scaffolds
Lv, Y., Wang, H., Li, G., & Zhao, B. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.004 · Cited by 67
Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
de Haart, S. J., van de Donk, N. W. C. J., Minnema, M. C., Huang, J. H. Y., Aarts‐Riemens, T., Bovenschen, N., Yuan, H., Groen, R. W. J., McMillin, D. W., Jakubı́ková, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3676 · Cited by 67
An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma
Silva, A., Silva, M. C., Sudalagunta, P. R., Graeter, A. I., Jacobson, T., Collins, A., Nguyen, T., Song, J., Chen, D., Chen, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0502 · Cited by 69
Self-citation
Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors
Chan, J. S. K., Sng, M. K., Teo, Z. Q., Chong, H. C., Twang, J. S., & Tan, N. S. (2017) · Oncogene · doi:10.1038/onc.2017.319 · Cited by 67
Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 83
“Bidirectional communication between tumor cells and the stroma triggers protective signaling cascades, contributing to what is termed Environment-Mediated Drug Resistance (EMDR) [143].”
CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1
Bhardwaj, A., Srivastava, S. K., Singh, S., Arora, S., Tyagi, N., Andrews, J., McClellan, S. B., Carter, J. E., & Singh, A. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2571 · Cited by 66
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma
Berestjuk, I., Lecacheur, M., Carminati, A., Diazzi, S., Rovera, C., Prod’homme, V., Ohanna, M., Popovic, A., Mallavialle, A., Larbret, F., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201911814 · Cited by 69
The cancer cell adhesion resistome: mechanisms, targeting and translational approaches
Dickreuter, E., & Cordes, N. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0326 · Cited by 67
Association of Cytokines and Chemokines in Pathogenesis of Breast Cancer
King, J., Mir, H., & Singh, S. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.07.003 · Cited by 66
Targeting PDK1 for Chemosensitization of Cancer Cells
Emmanouilidi, A., & Falasca, M. (2017) · Cancers · doi:10.3390/cancers9100140 · Cited by 66
Novel Points of Attack for Targeted Cancer Therapy
Røsland, G. V., & Engelsen, A. S. T. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12313 · Cited by 66
Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation
Castells, M., Milhas, D., Gandy, C., Thibault, B., Rafii, A., Delord, J., & Couderc, B. C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.384 · Cited by 65
Novel strategies for reversing platinum resistance
Shahzad, M. M. K., Lopez‐Berestein, G., & Sood, A. K. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.09.001 · Cited by 68
3D collagen type I matrix inhibits the antimigratory effect of doxorubicin
Millerot‐Serrurot, E., Guilbert, M., Fourré, N., Witkowski, W., Said, G., Gulick, L. V., Terryn, C., Zahm, J., Garnotel, R., & Jeannesson, P. (2010) · Cancer Cell International · doi:10.1186/1475-2867-10-26 · Cited by 65
A neutrophil membrane-functionalized black phosphorus riding inflammatory signal for positive feedback and multimode cancer therapy
Su, Y., Wang, T., Su, Y., Li, M., Zhou, J., Zhang, W., & Wang, W. (2019) · Materials Horizons · doi:10.1039/c9mh01068h · Cited by 65
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells
Balakrishnan, K., Burger, J. A., Quiroga, M. P., Henneberg, M., Ayres, M., Wierda, W. G., & Gandhi, V. V. (2010) · Blood · doi:10.1182/blood-2009-10-246199 · Cited by 64
Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication
Suh, D. H., Kim, H. S., Kim, B., & Song, Y. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.011 · Cited by 64
Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study
Nakashima, H., Matsuoka, Y., Yoshida, R., Nagata, M., Hirosue, A., Kawahara, K., Sakata, J., Arita, H., Hiraki, A., & Nakayama, H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2079-6 · Cited by 65
Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy
Kadel, D., Zhang, Y., Sun, H., Zhao, Y., Dong, Q., & Qin, L. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09461-z · Cited by 62
Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
Domen, A., Quatannens, D., Zanivan, S. R., Deben, C., Audenaerde, J. R. M. V., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., et al. (2021) · Cancers · doi:10.3390/cancers13050987 · Cited by 64
Pushing tumor cells towards a malignant phenotype: Stimuli from the microenvironment, intercellular communications and alternative roads
Marcucci, F., Bellone, M., Caserta, C. A., & Corti, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28572 · Cited by 64
Treatment resistance in urothelial carcinoma: an evolutionary perspective
Vlachostergios, P. J., & Faltas, B. M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0026-y · Cited by 62
The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment
Steele, A. J., Prentice, A. G., Cwynarski, K., Hoffbrand, A. V., Hart, S., Lowdell, M. W., Samuel, E. R., & Wickremasinghe, R. G. (2010) · Blood · doi:10.1182/blood-2009-09-245811 · Cited by 62
Investigating Breast Cancer Cell Behavior Using Tissue Engineering Scaffolds
Guiro, K., Patel, S. A., Greco, S. J., Rameshwar, P., & Arinzeh, T. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118724 · Cited by 66
Post-transcriptional regulation of the mitochondrial H+-ATP synthase: A key regulator of the metabolic phenotype in cancer
Willers, I. M., & Cuezva, J. M. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.016 · Cited by 65
Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer
Håkanson, M., Textor, M., & Charnley, M. (2010) · Integrative Biology · doi:10.1039/c0ib00074d · Cited by 62
Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
Beider, K., Darash‐Yahana, M., Blaier, O., Koren‐Michowitz, M., Abraham, M., Wald, H., Wald, O., Galun, E., Eizenberg, O., Peled, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0410 · Cited by 62
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer
Penkert, J., Ripperger, T., Schieck, M., Schlegelberger, B., Steinemann, D., & Illig, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11759 · Cited by 64
The role of cancer-associated fibroblasts in renal cell carcinoma. An example of tumor modulation through tumor/non-tumor cell interactions
Errarte, P., Larrinaga, G., & Lopez, J. I. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2019.09.004 · Cited by 60
The emerging role of exosomes in multiple myeloma
Moloudizargari, M., Abdollahi, M. R., Asghari, M. H., Zimța, A., Berindan‐Neagoe, I., & Nabavi, S. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100595 · Cited by 62
Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner
Azreq, M.-A. E., Naci, D., & Aoudjit, F. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-02-0132 · Cited by 64
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma
Meads, M. B., Fang, B., Mathews, L., Gemmer, J. Y., Nong, L., Rosado-Lopez, I., Nguyen, T., Ring, J., Matsui, W. H., MacLeod, A. R., et al. (2015) · Oncogene · doi:10.1038/onc.2015.334 · Cited by 60
Self-citation
A Functional Receptor for B-Cell–Activating Factor Is Expressed on Human Acute Lymphoblastic Leukemias
Parameswaran, R., Müschen, M., Kim, Y., Groffen, J., & Heisterkamp, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0300 · Cited by 60
Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling
Wu, G., Cao, L., Zhu, J., Tan, Z., Tang, M., Li, Z., Hu, Y., Yu, R., Zhang, S., Song, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2554 · Cited by 60
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
Kozalak, G., Bütün, İ., Toyran, E., & Koşar, A. (2023) · Pharmaceuticals · doi:10.3390/ph16010111 · Cited by 64
Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells
Nakagawa, Y., Nakayama, H., Nagata, M., Yoshida, R., Kawahara, K., Hirosue, A., Tanaka, T., Yuno, A., Matsuoka, Y., Kojima, T., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2265 · Cited by 59
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
Eldfors, S., Kuusanmäki, H. A., Kontro, M., Majumder, M. M., Parsons, A., Edgren, H., Pemovska, T., Kallioniemi, O., Wennerberg, K., Gökbuget, N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.202 · Cited by 59
Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
Gonçalves-Ribeiro, S., Díaz-Maroto, N. G., Berdiel‐Acer, M., Soriano, A., Guardiola, J., Martinez–Villacampa, M., Salazar, R., Capellá, G., Villanueva, A., Martinez‐Balibrea, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11121 · Cited by 59
Homeostasis Back and Forth: An Ecoevolutionary Perspective of CancerPreprint
Basanta, D., & Anderson, A. R. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028332 · Cited by 58
Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment
Becker, P. S. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/856467 · Cited by 58
Alpha2beta1 integrin promotes T cell survival and migration through the concomitant activation of ERK/Mcl-1 and p38 MAPK pathways
Naci, D., & Aoudjit, F. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.05.016 · Cited by 61
Osteoblastic and Vascular Endothelial Niches, Their Control on Normal Hematopoietic Stem Cells, and Their Consequences on the Development of Leukemia
Guerrouahen, B. S., Hijji, I. A., & Rafii, A. (2011) · Stem Cells International · doi:10.4061/2011/375857 · Cited by 63
Recent trends in cancer drug resistance reversal strategies using nanoparticles
Palakurthi, S., Yellepeddi, V., & Vangara, K. K. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.665365 · Cited by 57
3D cell coculture tumor model: A promising approach for future cancer drug discovery
Xin, X., Yang, H. K., Zhang, F., & Yang, S. (2018) · Process Biochemistry · doi:10.1016/j.procbio.2018.12.028 · Cited by 59
The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis
Goncharenko-Khaider, N., Matte, I., Lane, D. A., Rancourt, C., & Piché, A. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-84 · Cited by 57
Exosomes in Head and Neck Squamous Cell Carcinoma
Cheng, X., Song, F., Zheng, Y., Lv, J., Wang, Q. F., & Xu, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00894 · Cited by 58
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis
Cullinane, C. M., Creavin, B., O’Connell, E., Kelly, L., O’Sullivan, M. J., Corrigan, M. A., & Redmond, H. P. (2020) · British journal of surgery · doi:10.1002/bjs.11603 · Cited by 57
Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment
Zheng, D., Wan, C., Yang, H., Xu, L., Dong, Q., Du, C., Du, J., & Li, F. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s271213 · Cited by 56
Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy
Aliabadi, H. M., Maranchuk, R. A., Kucharski, C., Mahdipoor, P., Hugh, J. C., & Uludağ, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.012 · Cited by 56
Tumor–stromal cell interactions and opportunities for therapeutic intervention
Udagawa, T., & Wood, M. L. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.010 · Cited by 54
Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer
Kim, S., Lee, M., Dhanasekaran, D. N., & Song, Y. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-5152-5 · Cited by 56
Matrix stiffness mediates pancreatic cancer chemoresistance through induction of exosome hypersecretion in a cancer associated fibroblasts-tumor organoid biomimetic model
Xiao, W., Pahlavanneshan, M., Eun, C.-Y., Zhang, X., DeKalb, C., Mahgoub, B., Knaneh-Monem, H., Shah, S., Sohrabi, A., Seidlits, S. K., et al. (2022) · Matrix Biology Plus · doi:10.1016/j.mbplus.2022.100111 · Cited by 59
Engineered 3D Silk‐Based Metastasis Models: Interactions Between Human Breast Adenocarcinoma, Mesenchymal Stem Cells and Osteoblast‐Like Cells
Talukdar, S., & Kundu, S. C. (2013) · Advanced Functional Materials · doi:10.1002/adfm.201300312 · Cited by 56
Selected Aspects of Chemoresistance Mechanisms in Colorectal Carcinoma—A Focus on Epithelial-to-Mesenchymal Transition, Autophagy, and Apoptosis
Skarková, V., Králová, V., Vítovcová, B., & Rudolf, E. (2019) · Cells · doi:10.3390/cells8030234 · Cited by 55
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis
Holthof, L. C., van der Schans, J. J., Katsarou, A., Poels, R., Gelderloos, A. T., Drent, E., Veen, S. E. V. H.-V., Li, F., Zweegman, S., van de Donk, N. W. C. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2188 · Cited by 55
A Preclinical Assay for Chemosensitivity in Multiple Myeloma
Khin, Z. P., Ribeiro, M. L. C., Jacobson, T., Hazlehurst, L., Perez, L. E., Baz, R., Shain, K. H., & Silva, A. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2397 · Cited by 55
The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma
Matsuoka, Y., Yoshida, R., Nakayama, H., Nagata, M., Hirosue, A., Tanaka, T., Kawahara, K., Nakagawa, Y., Sakata, J., Arita, H., et al. (2014) · Apmis · doi:10.1111/apm.12344 · Cited by 54
The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance
Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00452-8 · Cited by 61
Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling
Yan, H., Guo, B.-Y., & Zhang, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.131 · Cited by 54
Targeting E-selectin to Tackle Cancer Using Uproleselan
Muz, B., Abdelghafer, A., Markovic, M., Yavner, J., Melam, A., Salama, N. N., & Azab, A. K. (2021) · Cancers · doi:10.3390/cancers13020335 · Cited by 54
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Qin, A., Musket, A., Musich, P. R., Schweitzer, J. B., & Xie, Q. R. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab133 · Cited by 55
Mathematical Oncology
Anderson, A. R. A., & Maini, P. K. (2018) · Bulletin of Mathematical Biology · doi:10.1007/s11538-018-0423-5 · Cited by 55
Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
Tian, X., Yan, T., Liu, F., Liu, Q., Zhao, J., Xiong, H., & Jiang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.991052 · Cited by 53
Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes
Alonso, S., Su, M., Jones, J. W., Ganguly, S., Kane, M. A., Jones, R. J., & Ghiaur, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3614 · Cited by 53
Adhesion Deregulation in Acute Myeloid Leukaemia
Gruszka, A., Valli, D., Restelli, C., & Alcalay, M. (2019) · Cells · doi:10.3390/cells8010066 · Cited by 55
Animal models of soft-tissue sarcoma
Dodd, R. D., Mito, J., & Kirsch, D. G. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.005223 · Cited by 52
Development of an in vitro cell-sheet cancer model for chemotherapeutic screening
Lee, J., Shin, D., & Roh, J. (2018) · Theranostics · doi:10.7150/thno.26439 · Cited by 52
Nanomedicine Against Multidrug Resistance in Cancer Treatment
Gao, J., Feng, S., & Guo, Y. (2012) · Nanomedicine · doi:10.2217/nnm.12.11 · Cited by 52
Underlying mechanisms and drug intervention strategies for the tumour microenvironment
Li, H., Zhou, L., Zhou, J., Li, Q., & Ji, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01893-y · Cited by 51
ErbB2 Stabilizes Epidermal Growth Factor Receptor (EGFR) Expression via Erk and Sprouty2 in Extracellular Matrix-detached Cells
Grassian, A. R., Schafer, Z. T., & Brugge, J. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.169821 · Cited by 51
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
Vareki, S. M., Rytelewski, M., Figueredo, R., Chen, D., Ferguson, P. J., Vincent, M. D., Min, W., Zheng, X., & Koropatnick, J. D. (2014) · Oncotarget · doi:10.18632/oncotarget.1916 · Cited by 53
Network dynamics in the tumor microenvironment
Bolouri, H. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.007 · Cited by 51
CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer
Au, K. K., Peterson, N. T., Truesdell, P. F., Reid‐Schachter, G., Khalaj, K., Ren, R., Francis, J., Graham, C. H., Craig, A. W., & Koti, M. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.03.007 · Cited by 51
Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Guillén Díaz-Maroto, N., Sanz-Pamplona, R., Berdiel-Acer, M., Cimas, F. J., García, E., Gonçalves-Ribeiro, S., Albert, N., Garcia-Vicién, G., Capella, G., Moreno, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3957 · Cited by 51
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
Deng, D., Patel, R. H., Chiang, C.-Y., & Hou, P. (2022) · Cells · doi:10.3390/cells11192952 · Cited by 53
Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma
Bonneau, C., Rouzier, R., Geyl, C., Cortez, A., Castela, M., Lis, R., Daraï, É., & Touboul, C. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.024 · Cited by 50
Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway
Zhang, L., & Zou, W. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4443 · Cited by 50

Authors: Meads, M. B., Gatenby, R. A., & Dalton, W. S.
Affiliations: Moffitt Cancer Center (US)
Corresponding author: Dalton, William S.
ORCID: Meads, Mark B.
Gatenby, Robert A.
Dalton, William S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-08-20
Volume: 9
Issue: 9
Pages: 665-674
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2714
OpenAlex: W2066616821
Cited by: 892
References: 109
Citations by year: 2026: 33 · 2025: 44 · 2024: 35 · 2023: 55 · 2022: 54 · 2021: 74 · 2020: 65 · 2019: 58 · 2018: 56 · 2017: 52 · 2016: 68 · 2015: 61 · 2014: 64 · 2013: 51 · 2012: 52
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: tumor microenvironment, minimal residual disease, recurrence, acquired drug resistance, stromal factors, adjuvant therapy, cancer therapy resistance
MeSH terms: Humans, Neoplasms, Signal Transduction, Stromal Cells, Neoplasm, Residual, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Environment-mediated drug resistance: a major contributor to minimal residual disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks